TherOptix develops targeted therapies for anterior and posterior ocular conditions using advanced drug delivery systems. The company addresses the need for effective treatment options in ophthalmology, enhancing patient outcomes and reducing the burden of eye diseases.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for anterior and posterior ocular conditions often lack targeted drug delivery, leading to suboptimal therapeutic outcomes and increased side effects. Effective treatment options are needed to improve patient outcomes and reduce the burden of eye diseases.
Solution
TherOptix is developing advanced drug delivery systems to create targeted therapies for both anterior and posterior ocular conditions. Their approach aims to enhance the precision and efficacy of ophthalmic treatments, ensuring that medication reaches the affected tissues directly. By focusing on targeted delivery, TherOptix seeks to minimize off-target effects and maximize the therapeutic impact, ultimately improving patient outcomes in the treatment of various eye diseases. The company's pipeline focuses on innovative solutions to address unmet needs in ophthalmology.
Target Audience
The primary target audience includes patients suffering from anterior and posterior ocular conditions, as well as ophthalmologists and other eye care professionals seeking more effective treatment options.
Features
- Targeted drug delivery systems for anterior ocular conditions
- Targeted drug delivery systems for posterior ocular conditions
- Development of therapies to enhance the precision and efficacy of ophthalmic treatments